Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting

The European Journal of Health Economics - Although high-throughput sequencing is revolutionising medicine, data on the actual cost of whole exome sequencing (WES) applications are needed. We aimed...     

Conventional and advanced imaging throughout the cycle of care of gliomas

Neurosurgical Review - Although imaging of gliomas has evolved tremendously over the last decades, published techniques and protocols are not always implemented into clinical practice. Furthermore,...     

Scientific Advances and New Frontiers in Mesothelioma Therapeutics

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.     

White finger and hypertrophy of the lumbrical muscles

Within the digital vascularization diseases, we found a compression of the radial and ulnar collateral arteries of a finger by hypertrophy of the lumbrical muscles which was presented clinically in the form of a chronic sub-ischemia. A surgical release made it possible to recover a vascularized and sensitive finger.     

Stability of nystatin in mouthrinses; effect of pH, temperature, concentration and colloidal silver addition, studied using an in vitro antifungal activity.

Alkaline low concentration nystatin mouthrinses extemporanely prepared can be used to treat oropharyngeal candidiasis in immunodeficient patients. However, their expiration dates are not distinctly determined.The stability of nystatin, added (as Mycostatine) at a concentration of 14 400 U/ml in 10^–4 N hydrochloric acid, purified water and 1.4% injectable sodium hydrogen carbonate with or without 0.002% colloidal silver (an antiseptic agent added because of its known antifungal potency) was studied after storage in tinted glass bottles at 5 °C and 22 °C over 11 days, and compared with reconstituted 100 000 U/ml aqueous Mycostatine oral suspension. At 2, 4, 7, 9, and 11 days after preparation. Samples were tested for pH, microbial contamination, and assayed by an in vitro microbiological test.Neither significant variation of pH nor microbial contamination were in evidence. Nystatin 14 400 U/ml maintained at least 90% of its initial concentration for 4 days in acid at both temperatures, for 7 days (5 °C) and 4 days (22 °C) in aqueous and alkaline environments, for 9 days (5 °C) and 7 days (22 °C) in 1.4% injectable sodium hydrogen carbonate containing colloidal silver which showed an antifungal potency. The 100 000 U/ml aqueous Mycostatine oral suspension was stable for 9 days and 4 days at 5 °C and 22 °C respectively.An ambulant patient can keep a low concentration alkaline antifungal mouthrinse at home for a week at 5 °C.